Similarly, pharmacological suppression of PFKFB3 elicits anti-inflammatory and antifibrotic effects in experimental pulmonary fibrosis, concurrently diminishing NLRP3 activation (Liu C, et al., 2024). This evidence concerns the gene PFKFB3 and pulmonary fibrosis.